Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00046696 | A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. | PHASE1 | COMPLETED | 32 | — | — | May 1, 2001 | Oct 1, 2006 | May 20, 2015 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| NM-3 | DRUG | - |
Inclusion Criteria: * Adult patients at least 18 years of age. * All patients must have an advanced solid tumor that has failed standard therapy or for which no standard therapy exists. * Histological or cytological diagnosis of a malignant solid tumor. * Measurable or non-measurable disease. * Any...